Posts Tagged ‘Low molecular weight heparin’
A new guideline about the prevention, diagnosis, and treatment of DVT and PE associated with pregnancy was published today by ACOG (American College of Obstetricians and Gynecologists) in its respected series of Practice Bulletins. The bulletin also takes detailed reference to prevention of blood clots in pregnant women with thrombophilia. Read the rest of this entry »
Occasionally, a patient is treated with long-term low molecular weight heparin (LMWH) (enoxaparin = Lovenox®; Dalteparin = Fragmin®; Tinzaparin = Innohep®) for months or years. LMWH may be given because the patient (a) tolerated warfarin poorly (widely fluctuating INRs; significant side-effects, such as marked hair loss or fatigue), (b) had a recurrent clot which occured on warfarin with a therapeutic INR, or (c) is pregnant and LMWH is the preferred “blood thinner” during pregnancy in women at increased risk for blood clots. The main side-effect of long-term LMWH is, of course, bleeding.
Whether LMWH causes osteoporosis (=loss of bone mass) is not known, Read the rest of this entry »
How common is it?
Hair loss is a known side effect of warfarin (Coumadin®, Jantoven®), but has hardly been studied [ref 1]. Solid data on how frequently it occurs, on its time-course, and on treatments are not available. Mild hair loss appears to be common, severe hair loss uncommon, complete hair loss has not been reported. Read the rest of this entry »
What Is HIT?
Heparin-induced thrombocytopenia (HIT) is a serious side effect that may occur when you are being treated with heparin. It may lead to low blood platelet counts and to life-threatening blood clots. Read the rest of this entry »